Avamys Nasal Spray 27.5 mcg/spray

SPRAY, SUSPENSION

**Dosage and Administration** _AVAMYS_ Nasal Spray is for administration by the intranasal route only. For full therapeutic benefit regular scheduled usage is recommended. Onset of action has been observed as early as 8 hours after initial administration. It may take several days of treatment to achieve maximum benefit. An absence of an immediate effect should be explained to the patient _(see Clinical Studies_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _)_. **Populations** For the treatment of seasonal allergic rhinitis and perennial allergic rhinitis: **Adults and Adolescents (12 years and older)** The recommended starting dosage is 2 sprays (27.5 micrograms per spray) in each nostril once daily (total daily dose, 110 micrograms). Once adequate control of symptoms is achieved, dose reduction to 1 spray in each nostril once daily (total daily dose, 55 micrograms) may be effective for maintenance. **Children (2 to 11 years)** The recommended starting dosage is 1 spray (27.5 micrograms per spray) in each nostril once daily (total daily dose, 55 micrograms). Patients not adequately responding to 1 spray in each nostril once daily (total daily dose, 55 micrograms) may use 2 sprays in each nostril once daily (total daily dose, 110 micrograms). Once adequate control of symptoms is achieved, dose reduction to 1 spray in each nostril once daily (total daily dose, 55 micrograms) is recommended. **Children (under 2 years of age)** There are no data to recommend use of intranasal fluticasone furoate for the treatment of seasonal or perennial allergic rhinitis in children under 2 years of age. **Elderly** No dosage adjustment required _(see Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _)_. **Renal impairment** No dosage adjustment required _(see Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _)_. **Hepatic impairment** No dosage adjustment is required in patients with hepatic impairment _(see Warnings and Precautions, and Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _)_.